This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.70% per year. These returns cover a period from January 1, 1988 through April 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
Time to Rotate to Cyclical Sector ETFs?
by Sanghamitra Saha
U.S. stocks have been super steady this week on Pfizer's upbeat vaccine data and chances of a divided Congress in the United States.
ETF Areas to Win/Lose With Biden on the Verge of Victory
by Sanghamitra Saha
Though the counting process for the U.S. election outcome is still on, the prospect of a Joe Biden presidency marked by a divided Congress is rife.
Wining & Losing Sector ETFs Post Election Day
by Sanghamitra Saha
Chances of a dividend congress caused a superb rally in Wall Street the day after election.
Bank Stocks Tank on Sharp Fall in Treasury Yields, Uncertainty
by Priti Dhanuka
Bank stocks plummet on sharp fall in Treasury yields, bucking the rally in the broader market.
Why Bank ETFs Are Surging
by Sweta Killa
As banks seek to borrow money at short-term rates and lend at long-term rates, a steepening yield curve will earn more on lending and pay less on deposits, thereby leading to a wider spread.
Bank ETFs Surge as Yield Curve Steepens
by Sweta Killa
The banking corner of the broader financial sector is back on track this month owing to the steepening of the yield curve. Will the strong trend continue?
3 Reasons to Be Wary of Bank ETFs
by Sanghamitra Saha
Chances of higher virus cases in winter, Biden???s considerable chances of winning the election and low rates for longer may spell trouble for bank ETFs ahead.
Biden's Corporate Tax Plan Could Spell Trouble for Bank ETFs
by Sweta Killa
Biden proposed corporate tax hike from 21% to 28% would drop net income by more than $7 billion per year for the nation's 10 largest banks.
Bank Stocks Down as Probe Shows Large Scale Money Laundering
by Swayta Shah
The report revealing rampant money laundering shows that efforts taken by banks to fight such activities are still not enough. The disclosure hurt the banks' reputation to an extent.
Is It Again Time to Shift Focus to Cyclical ETFs?
by Sanghamitra Saha
AstraZeneca has restarted British clinical trials of its COVID-19 vaccine. This piece of information may help boost cyclical ETFs all over again.